A Multi-Center, Randomized Evaluation of Treatment Outcomes in Patients with De Novo Coronary Atherosclerotic Lesions Treated with the Conor Sirolimus-eluting Coronary Stent System compared to the TAXUS Liberte Paclitaxel-eluting Coronary System Assessed by Angiographic Late Loss at Six Months

Conor Medsystems, LLC0 个研究点目标入组 388 人开始时间: 2008年4月14日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•The subject is eligible for percutaneous coronary intervention and coronary artery bypass graft surgery,
•The subject has a diagnosis of stable or unstable angina, or silent ischemia,
•The subject has a left ventricular ejection fraction >30%,
•The subject requires treatment of a single de novo lesion in a native coronary artery,
•The subject understands the study requriements, is willing to comply with all study procedures and has provided written informed consent.

•The subject has undergone prior coronary artery bypass graft surgery, prior coronary brachytherapy, prior coronary stent implant to the target vessel, prior coronary intervention within 30 days, or prior revascularization to the target vessel within the previous 6 months.
•The subject has experienced recent myocardial infarction within 72 hours.
•The subject has experienced a cerebrovascular accident within the last 6 months, active gastrointestinal bleeding within the last 3 months, has a known bleeding disorder, hypercoagulable disorder or thrombocytopenia.
•The subject is a female of childbearing potential with a positive pregnancy test or is lactating.
•The subject has co-morbidities that could interfere with completion of study procedures, or life expectancy less than 24 months.

发起方